drugset / Trial / NCT02554695
Osteoclast Inhibition and Bone Formation
RandomizedParallel-groupQuadruple-blindBasic science
Summary
This protocol addresses: 1) How gene expression changes in bone cells are affected by aging? 2) Is aging associated with decreased signaling between bone cells? 3) How does treatment with the osteoporosis medication denosumab affect bone cell signaling?
Timeline
- Start
- 2015-10-20
- Primary completion
- 2016-10-25
- Completion
- 2016-10-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Denosumab | Monoclonal antibody | 60 mg | Subcutaneous |